{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:38:24Z","timestamp":1775471904499,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cancer patients receiving targeted therapies need to prevent QTc prolongation and life-threatening cardiovascular (CV) events to maintain a balanced benefit-risk ratio. This study aimed to develop an optimal prediction model for QTc prolongation risk and estimate its risk probability in cancer patients treated with oral tyrosine kinase inhibitors (TKIs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective cohort study analyzed electronic medical records (EMR) of cancer patients newly treated with commonly used oral TKIs at a medical center between January 2016 and December 2020. QTc prolongation was defined as\u2009\u2265\u2009450\u00a0ms in males and\u2009\u2265\u2009470\u00a0ms in females using Bazett\u2019s formula. The study followed four key steps: (1) Managing missing data, (2) Identifying important variables, (3) Training and testing the best prediction models, (4). Estimating risk probability and determining cut-off points. Both univariate logistic regression (LR) and supervised machine learning (ML) approaches were used for variable selection. The backward LR method and seven ML algorithms were applied to train and test the prediction models. The best model was identified based on model performance, fitting criteria, area under the receiver operating characteristic curve (AUROC), risk probability cut-off points, and clinical relevance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The statistical 12-parameter model demonstrated excellent performance (AUROC\u2009=\u20090.89, sensitivity\u2009=\u20090.91, specificity\u2009=\u20090.75) and strong discrimination ability for risk probability prediction (AUROC\u2009=\u20090.78, cut-off\u2009=\u20090.46), outperforming other ML models. In the final best model: the baseline risk probability of QTc prolongation was 0.13, even in the absence of other contributing factors. Baseline QTc prolongation and a history of cardiovascular disease (excluding arrhythmia, cardiomyopathy, etc.) contributed the most to incremental risk probability (0.471 and 0.282, respectively), after controlling for other factors. The remaining 10 factors each contributed to an increased probability of QTc prolongation for more than 0.14 probability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A logistic regression model utilizing 12 easily accessible variables from EMRs outperformed ML models in predicting the risk probability of QTc prolongation in cancer patients newly treated with five oral TKIs. These findings serve as a valuable clinical reference for integrating digital monitoring into cardiovascular care for cancer survivors undergoing targeted therapy with TKIs. They also underscore the importance of screening baseline ECG before initiating TKIs to assess the risk of QTc prolongation, facilitating early intervention and prevention in the future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12911-025-03091-8","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T08:55:04Z","timestamp":1755248104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-6746","authenticated-orcid":false,"given":"Hsiang-Wen","family":"Lin","sequence":"first","affiliation":[]},{"given":"Tien-Chao","family":"Lin","sequence":"additional","affiliation":[]},{"given":"Chien-Ning","family":"Hsu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2620-0591","authenticated-orcid":false,"given":"Tzu-Pei","family":"Yeh","sequence":"additional","affiliation":[]},{"given":"Yu-Chieh","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Liang-Chih","family":"Liu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-0959","authenticated-orcid":false,"given":"Chen-Yuan","family":"Lin","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"1","key":"3091_CR1","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1186\/s12885-021-08707-6","volume":"21","author":"P Yang","year":"2021","unstructured":"Yang P, Zheng Y, Chen J, et al. Immediate risk of non-cancer deaths after a cancer diagnosis. BMC Cancer. 2021;21(1):963. https:\/\/doi.org\/10.1186\/s12885-021-08707-6.","journal-title":"BMC Cancer"},{"issue":"1","key":"3091_CR2","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/s41467-020-15639-5","volume":"11","author":"KC Stoltzfus","year":"2020","unstructured":"Stoltzfus KC, Zhang Y, Sturgeon K, et al. Fatal heart disease among cancer patients. Nat Commun. 2020;11(1):2011. https:\/\/doi.org\/10.1038\/s41467-020-15639-5.","journal-title":"Nat Commun"},{"key":"3091_CR3","doi-asserted-by":"publisher","first-page":"1014400","DOI":"10.3389\/fcvm.2023.1014400","volume":"10","author":"Z Wang","year":"2023","unstructured":"Wang Z, Fan Z, Yang L, et al. Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors. Fron Cardiovasc Med. 2023;10:1014400.","journal-title":"Fron Cardiovasc Med"},{"issue":"2","key":"3091_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/annonc\/mdw604","volume":"28","author":"NG Zaorsky","year":"2017","unstructured":"Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400\u201307. https:\/\/doi.org\/10.1093\/annonc\/mdw604.","journal-title":"Ann Oncol"},{"issue":"2","key":"3091_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jaccao.2022.05.001","volume":"4","author":"MA Mamas","year":"2022","unstructured":"Mamas MA, Matetic A. How common is pre-existing cardiovascular disease in cancer patients. JACC: CardioOncology. 2022;4(2):254\u201357. https:\/\/doi.org\/10.1016\/j.jaccao.2022.05.001","journal-title":"JACC: CardioOncology"},{"key":"3091_CR6","doi-asserted-by":"publisher","unstructured":"Porta-S\u00e1nchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc. 2017;6(12):e007724. https:\/\/doi.org\/10.1161\/JAHA.117.007724.","DOI":"10.1161\/JAHA.117.007724"},{"issue":"11","key":"3091_CR7","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/ijc.33119","volume":"147","author":"AA Abu Rmilah","year":"2020","unstructured":"Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer. 2020;147(11):3160\u201367. https:\/\/doi.org\/10.1002\/ijc.33119","journal-title":"Int J Cancer"},{"issue":"3","key":"3091_CR8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005 Dec;315(3):971\u201379. https:\/\/doi.org\/10.1124\/jpet.105.084145. Epub 2005 Jul 7. PMID: 16002463","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3091_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore SD, Kohnken RA, Peters MF, Kolaja KL. Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem Res Toxicol. 2020;33(1):125\u201336. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00387","journal-title":"Chem Res Toxicol"},{"key":"3091_CR10","doi-asserted-by":"publisher","unstructured":"Shim JV, Chun B, van Hasselt JGC, et al. Mechanistic systems modeling to improve understanding and prediction of cardiotoxicity caused by targeted cancer therapeutics. Front Physiol. 2017;8. https:\/\/doi.org\/10.3389\/fphys.2017.00651.","DOI":"10.3389\/fphys.2017.00651"},{"issue":"5","key":"3091_CR11","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.3390\/ijms23052815","volume":"23","author":"A Grela-Wojewoda","year":"2022","unstructured":"Grela-Wojewoda A, Pacholczak-Madej R, Adamczyk A, Korman M, P\u00fcsk\u00fcll\u00fco\u011flu M. Cardiotoxicity induced by protein kinase inhibitors in patients with cancer. Int J Mol Sci. 2022;23(5):2815. https:\/\/doi.org\/10.3390\/ijms23052815","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3091_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2125.2010.03660.x","volume":"70","author":"C Van Noord","year":"2010","unstructured":"Van Noord C, Eijgelsheim M, Stricker BH. Drug-and non-drug-associated QT interval prolongation. Br J Clin Pharmacol. 2010;70(1):16\u201323. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03660.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3091_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479\u201387. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.113.000152.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"12","key":"3091_CR14","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1111\/bcp.13740","volume":"84","author":"E Vandael","year":"2018","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, et al. A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model. Br J Clin Pharmacol. 2018;84(12):2824\u201335. https:\/\/doi.org\/10.1111\/bcp.13740.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"3091_CR15","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.3390\/cimb45100526","volume":"45","author":"Y Samuel","year":"2023","unstructured":"Samuel Y, Babu A, Karagkouni F, Ismail A, Choi S, Boussios S. Cardiac toxicities in oncology: elucidating the dark box in the era of precision medicine. Curr Issues Mol Biol. 2023;45(10):8337\u201358. https:\/\/doi.org\/10.3390\/cimb45100526","journal-title":"Curr Issues Mol Biol"},{"issue":"12","key":"3091_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10916-022-01890-4","volume":"46","author":"S Van Laere","year":"2022","unstructured":"Van Laere S, Muylle KM, Dupont AG, Cornu P. Machine learning techniques outperform conventional statistical methods in the prediction of high risk QTc prolongation related to a drug-drug interaction. J Med Syst. 2022;46(12):100. https:\/\/doi.org\/10.1007\/s10916-022-01890-4","journal-title":"J Med Syst"},{"issue":"4","key":"3091_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1074248421995348","volume":"26","author":"ST Simon","year":"2021","unstructured":"Simon ST, Mandair D, Tiwari P, Rosenberg MA. Prediction of drug-induced long QT syndrome using machine learning applied to harmonized electronic health record data. J Cardiovasc Pharmacol Ther. 2021;26(4):335\u201340. https:\/\/doi.org\/10.1177\/1074248421995348","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"3091_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.tcm.2017.07.010","volume":"28","author":"RL Woosley","year":"2018","unstructured":"Woosley RL, Black K, Heise CW, Romero K. CredibleMeds.org: what does it offer? Trends Cardiovasc Med. 2018;28(2):94\u201399. https:\/\/doi.org\/10.1016\/j.tcm.2017.07.010","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"3091_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424\u201332. https:\/\/doi.org\/10.1007\/s11096-017-0446-2","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"3091_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.hrthm.2007.02.025","volume":"4","author":"CA Remme","year":"2007","unstructured":"Remme CA, Bezzina CR. Genetic modulation of cardiac repolarization reserve. Heart Rhythm. 2007;4(5):608\u201310. https:\/\/doi.org\/10.1016\/j.hrthm.2007.02.025","journal-title":"Heart Rhythm"},{"issue":"11","key":"3091_CR21","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","volume":"89","author":"YG Yap","year":"2003","unstructured":"Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363\u201372. https:\/\/doi.org\/10.1136\/heart.89.11.1363","journal-title":"Heart"},{"issue":"1","key":"3091_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11096-016-0414-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16\u201325. https:\/\/doi.org\/10.1007\/s11096-016-0414-2","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"3091_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479\u201387. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.113.000152.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"19","key":"3091_CR24","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/eurheartj\/ehi312","volume":"26","author":"SM Straus","year":"2005","unstructured":"Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26(19):2007\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehi312.","journal-title":"Eur Heart J"},{"issue":"2","key":"3091_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jacc.2005.08.067","volume":"47","author":"SM Straus","year":"2006","unstructured":"Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47(2):362\u201367. https:\/\/doi.org\/10.1016\/j.jacc.2005.08.067.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3091_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/cvr\/cvz013","volume":"115","author":"DM Roden","year":"2019","unstructured":"Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895\u2013903. https:\/\/doi.org\/10.1093\/cvr\/cvz013","journal-title":"Cardiovasc Res"},{"issue":"10","key":"3091_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013\u201322. https:\/\/doi.org\/10.1056\/NEJMra032426","journal-title":"N Engl J Med"},{"issue":"5","key":"3091_CR28","first-page":"296","volume":"48","author":"KP Letsas","year":"2007","unstructured":"Letsas KP, Efremidis M, Filippatos GS, Sideris AM. Drug-induced long QT syndrome. Hellenic J Cardiol. 2007;48(5):296\u201399.","journal-title":"Hellenic J Cardiol"},{"issue":"4","key":"3091_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.mayocp.2013.01.013","volume":"88","author":"KH Haugaa","year":"2013","unstructured":"Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution-Wide QT Alert system identifies patients with a high risk of mortality. Mayo Clin Proc. 2013;88(4):315\u201325. https:\/\/doi.org\/10.1016\/j.mayocp.2013.01.013","journal-title":"Mayo Clin Proc"},{"key":"3091_CR30","doi-asserted-by":"publisher","unstructured":"Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;Suppl 7:vii173-vii179. https:\/\/doi.org\/10.1093\/annonc\/mdq295.","DOI":"10.1093\/annonc\/mdq295"},{"key":"3091_CR31","unstructured":"World Health Organization. Defined Daily Dose (DDD) https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd Available By. July 30, 2024."},{"issue":"2","key":"3091_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1542-474X.1997.tb00325.x","volume":"2","author":"HC Bazett","year":"1997","unstructured":"Bazett HC. An analysis of the time-relations of electrocardiograms. Ann Noninvasive Electrocardio. 1997;2(2):177\u201394. https:\/\/doi.org\/10.1111\/j.1542-474X.1997.tb00325.x","journal-title":"Ann Noninvasive Electrocardio"},{"issue":"39","key":"3091_CR33","doi-asserted-by":"publisher","first-page":"25738","DOI":"10.18632\/oncotarget.25008","volume":"9","author":"J Duan","year":"2018","unstructured":"Duan J, Tao J, Zhai M, et al. Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 2018;9(39):25738\u201349. https:\/\/doi.org\/10.18632\/oncotarget.25008.","journal-title":"Oncotarget"},{"issue":"6","key":"3091_CR34","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/anec.12161","volume":"19","author":"D Patel","year":"2014","unstructured":"Patel D, Singh P, Katz W, et al. QT interval prolongation in end-stage liver disease cannot be explained by nonhepatic factors. Ann Noninvasive Electrocardiol. 2014;19(6):574\u201381. https:\/\/doi.org\/10.1111\/anec.12161.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"2","key":"3091_CR35","doi-asserted-by":"publisher","first-page":"e12696","DOI":"10.1111\/anec.12696","volume":"25","author":"CN Majeed","year":"2020","unstructured":"Majeed CN, Ahmad MI, Ahsan I, et al. Relation of total bilirubin and QT interval prolongation (from the Third National Health and Nutrition Examination Survey). Ann Noninvasive Electrocardiol. 2020;25(2):e12696. https:\/\/doi.org\/10.1111\/anec.12696.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"10","key":"3091_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.31083\/j.rcm2410296","volume":"24","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Chen Z, Huang S, et al. Machine learning in cardio-oncology: new insights from an emerging discipline. Rev Cardiovasc Med. 2023;24(10):296. https:\/\/doi.org\/10.31083\/j.rcm2410296.","journal-title":"Rev Cardiovasc Med"},{"issue":"3","key":"3091_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bimj.201700067","volume":"60","author":"G Heinze","year":"2018","unstructured":"Heinze G, Wallisch C, Dunkler D. Variable selection - A review and recommendations for the practicing statistician. Biom J. 2018;60(3):431\u201349. https:\/\/doi.org\/10.1002\/bimj.201700067","journal-title":"Biom J"},{"issue":"2","key":"3091_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.17482\/uumfd.1296479","volume":"28","author":"\u00dc Yilmaz","year":"2023","unstructured":"Yilmaz \u00dc, Kuvat \u00d6. Invstigating the effect of feature selection methods on the success of overall equipment effectiveness prediction. Uludag \u00dcniversitesi J Fac Eng. 2023;28(2):437\u201352. https:\/\/doi.org\/10.17482\/uumfd.1296479","journal-title":"Uludag \u00dcniversitesi J Fac Eng"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-025-03091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-025-03091-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-025-03091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:13:48Z","timestamp":1757391228000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-025-03091-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3091"],"URL":"https:\/\/doi.org\/10.1186\/s12911-025-03091-8","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was waived for this retrospective EMR review. The study protocol was approved by the Research Ethics Committee (Institutional Review Board [IRB] of China Medical University Hospital (CMUH): CMUH109-REC2-122). This study meets the criteria of waving the inform consent because we used \u201cde-identified\u201d data, which were retrospectively collected and processed by the information technology (IT) center through formal application process in this specific hospital upon the request of the available reginal IRB. Specifically, the used data cannot be identified for the personal information after being processed by the IT center. In Taiwan, it is emphasized that \u201cas for the personal data regarding medical records, medical treatment, genetics, sexual life, health examinations and criminal records, which were prepared or collected by public agencies or medical\/academic research institutes for medical, health or crime prevention purposes, only the data meet the following criteria can be used to fulfill the necessity of analysis purpose or academic research: data cannot be identified for the personal information after being processed by the providers or which were collected through deidentify the personal information based on the method of disclosure\u201d. Thus, the aforementioned data can be used without having inform consents from patients or individuals, upon the \u201cPersonal Data Protection Law\u201d announced by the Committee of Personal Data Protection, Executive Yuan, Taiwan, and approved by CMUH IRB accordingly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"310"}}